ClinicalTrials.gg
Active, not recruitingNCT04623541EPCORE™ CLL-1Updated Nov 4, 2026

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

A Phase 1/2 interventional study of Epcoritamab and Epcoritamab in Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and Richter's Syndrome, sponsored by Genmab. Active, not recruiting at 81 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Genmab · Phase 1/2, Interventional, and Treatment

Updated Oct 6, 202617 sites added17 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
194
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States — 138 open to participants now, 252 under way, 34 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · United States.

Enrollment
134th of 1,298
194 · median 36
Started
2020
with 49 others
Phase 1/2
172 of 1,501
15 open now
Primary completion
2027-12
later than 148 of 248 live
Registered
1,304th of 1,501
by date

Among the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, this one is the 134th largest by enrollment of the 1,298 interventional ones that give a count, is one of 50 that started in 2020, is one of 172 in phase 1/2, reaches primary completion later than 148 of the 248 other live ones, and was the 1,304th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

138 of the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States are open now. Recruiting first, the newest first:

133 more — sign in →

All 138 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, or all of them as a file.
02

Study summary

The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20). Epcoritamab will be tested either in

Relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as:

  • Monotherapy, or
  • Combination therapy:

    • epcoritamab + venetoclax
    • epcoritamab + pirtobrutinib

In Non-United States (US) Participants Only: Treatment-naïve (TN) high risk (HR) (CLL):

  • epcoritamab + pirtobrutinib

Combination therapy for Richter's Syndrome (RS):

  • epcoritamab + lenalidomide
  • epcoritamab + R-CHOP (i.e., rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine [Oncovin®] and prednisone).

The study includes participants with R/R or TN HR CLL (non-US participants only)/small lymphocytic lymphoma (SLL) and participants with RS.

The trial consists of two parts, a dose-escalation phase (phase Ib) and an expansion phase (phase II). Participants with RS are only included in the expansion phase.

Epcoritamab will be injected subcutaneously (under the skin). Standard-of-care and combination treatments (venetoclax, pirtobrutinib, lenalidomide, and R-CHOP) will be given either orally (by mouth) or intravenously (in a vein).

Study details include:

  • Study duration will be up to 5 years after the last participant's first treatment in the trial.
  • The treatment duration for each participant will be between 12 months (1 year) and 24 months (2 years), depending upon the treatment arm assigned.
  • The visit frequency will be either weekly, every other week, or monthly, depending upon the part of the study.

All participants will receive active drug; no one will be given placebo.

Read the detailed description

The purpose of the dose-escalation phase of the trial is to determine the recommended phase 2 dose (RP2D) and the maximum tolerated dose (MTD; if reached) as well as establish the safety profile of epcoritamab monotherapy and epcoritamab + venetoclax in participants with R/R CLL.

The purpose of the expansion phase is to assess and evaluate the preliminary efficacy, safety and tolerability profiles of epcoritamab monotherapy, epcoritamab + venetoclax and epcoritamab + pirtobrutinib at the RP2D for participants with R/R CLL, TN HR CLL (in non-US participants only) and SLL. Along with this, epcoritamab monotherapy, epcoritamab + lenalidomide and epcoritamab + R-CHOP will be evaluated in participants with RS to assess their efficacy, safety and tolerability profiles.

The purpose of safety run-in phase for pirtobrutinib combination therapy is to evaluate the safety and tolerability profiles of pirtobrutinib in combination with epcoritamab.

03

Conditions studied

  • Relapsed/Refractory Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Richter's Syndrome
  • Treatment-naïve High Risk Chronic Lymphocytic Leukemia

Keywords

  • DuoBody®
  • Bispecific antibodies
  • Anti-CD3
  • Anti-CD20
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  1. (ECOG) performance status score of 0, 1 or 2.
  2. Evidence of CD20 positivity in a sample representative of the disease at Screening.
  3. Acceptable hematology parameters and organ function based on baseline bloodwork.
  4. >3 months on standard of care (SOC) for CLL, >3 months for RS.
  5. For R/R CLL arms - Must have active CLL/SLL disease requiring treatment per iwCLL 2018 criteria.
  6. For R/R CLL monotherapy arms - Received at least 2 prior lines of systemic anti-neoplastic therapy including a Bruton's tyrosine kinase (BTK) inhibitor or at least 1 prior line of systemic antineoplastic therapy, including treatment with (or intolerance of) a covalent BTK inhibitor (cBTKi) and a B-cell lymphoma 2 (BCL-2) inhibitor.
  7. For all RS arms - Have tumor -proven CD20+ Diffuse large B-cell Lymphoma (DLBCL) and a clinical history of CLL/SLL.
  8. For all RS arms - Must have by fluorodeoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT) or magnetic resonance imaging (MRI) scan.
  9. For all RS arms - Must provide mandatory formalin-fixed, paraffin-embedded (FFPE) tumor biopsy sample.
  10. For RS - monotherapy arm: Deemed as ineligible for chemoimmunotherapy at investigator's discretion or participant who refuses to receive intensive chemotherapy
  11. For RS - lenalidomide combination therapy arm

    • Deemed as ineligible for chemoimmunotherapy at the investigator's discretion, or participant who refuses to receive intensive chemotherapy.
    • Eligible for treatment with lenalidomide.
    • Must be willing to use and adhere to the Lenalidomide Pregnancy Risk Minimization Plan
    • A woman must agree not to breastfeed a child during treatment and for at least 28 days after discontinuation from study.
  12. For RS - R-CHOP combination Therapy Arm -

    • Eligible for treatment with R-CHOP.
    • Females of must use highly effective contraceptive measures while taking R-CHOP and for 12 months after stopping treatment.
    • A woman must agree not to breastfeed a child during treatment or until 12 months after last treatment.
  13. For R/R CLL - venetoclax combination Therapy arm - after receiving at least 1 prior line of systemic antineoplastic therapy.

    • Presence of measurable disease.
    • Must take prophylaxis for tumor lysis syndrome (TLS).
  14. For R/R CLL pirtobrutinib combination Therapy arm:

    • Must have active CLL/SLL disease requiring treatment per iwCLL 2018 criteria.
    • Presence of measurable disease.
    • Previous treatment with at least one and a maximum 3 including a cBTKi.
    • Diagnosis of CLL/SLL that met published iwCLL criteria.
  15. Non-US Participants Only - Participants with TN HR CLL - Pirtobrutinib Combination Therapy Expansion:

    • Diagnosis of CLL/SLL that met published iwCLL criteria 2018.
    • Must have active CLL/SLL disease that needs treatment per iwCLL
    • Must take prophylaxis for TLS based on their TLS risk evaluation upon initiation of trial drug.
    • Must have one or more high-risk features.
    • Presence of measurable disease.

Key Exclusion Criteria

  1. Received prior treatment with a CD3×CD20 bispecific antibody.
  2. Received any prior hematopoietic stem cell transplantation (HSCT) or solid organ transplantation.
  3. Received chimeric antigen receptor (CAR) T-cell therapy within 100 days or an drug within 4 weeks, prior to first dose of trial drug.
  4. disease or other diseases that require permanent or high-dose therapy.
  5. Received vaccination with within 28 days.
  6. cardiac disease.
  7. Known current other than inclusion diagnosis.
  8. Has had major surgery within 4 weeks.
  9. Known history of (HIV).
  10. For R/R CLL arms - Any history of RS or evidence indicating a potential Richter's transformation.
  11. For R/R CLL - Venetoclax Combination Therapy arm: received venetoclax within 24 months prior to beginning venetoclax ramp-up for this trial or has progressed on venetoclax treatment.
  12. For all RS arms - Diagnosis of Richter's syndrome not of the DLBCL subtype such as Hodgkin's lymphoma, prolymphocytic leukemia.
  13. RS - Lenalidomide Combination Therapy and RS Monotherapy Arms - received more than 2 prior lines of therapy for RS.
  14. R/R CLL - Pirtobrutinib Combination Therapy Arm - Prior exposure to a non-covalent (reversible) BTK inhibitor or a BTK degrader.
  15. Pirtobrutinib Combination Therapy Expansion Arms:

    • History of bleeding disorders or participants requiring therapeutic anticoagulation with warfarin or another vitamin K antagonist
    • Require continuous treatment with or have received strong cytochrome P450 (CYP) 3A inhibitors or strong/moderate inducers within 4 to 5 half-lives or 14 days prior to the first dose of pirtobrutinib.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
194 participants (actual)

Study arms

  • Experimental
    Epcoritamab in R/R CLL/SLL

    In both study phases. Participants in the expansion phase will be treated at the RP2D defined in the dose-escalation phase.

    Biological: Epcoritamab

  • Experimental
    Epcoritamab in RS

    Only in expansion phase.

    Biological: Epcoritamab

  • Experimental
    Epcoritamab + Venetoclax in R/R CLL/SLL

    In both study phases. Participants in the expansion phase will be treated at the RP2D defined in the dose-escalation phase.

    Biological: Epcoritamab · Drug: Venetoclax

  • Experimental
    Epcoritamab + Lenalidomide in RS

    Only in expansion phase.

    Biological: Epcoritamab · Drug: Lenalidomide

  • Experimental
    Epcoritamab + R-CHOP in RS

    Only in expansion phase.

    Biological: Epcoritamab · Drug: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone

  • Experimental
    Epcoritamab + Pirtobrutinib in R/R CLL, TN HR CLL (Non-US Participants Only) and SLL

    Safety run-in and expansion phases.

    Biological: Epcoritamab · Drug: Pirtobrutinib

  • Experimental
    Fixed Duration Epcoritamab in R/R CLL/SLL

    Only in expansion phase.

    Biological: Epcoritamab

Interventions

  • BiologicalEpcoritamab

    Epcoritamab will be administered subcutaneously in cycles of 28 days, (except Cycle 1 for high-dose cohorts = 35 days).

    Also known as: EPKINLY™, GEN3013, DuoBody®-CD3xCD20

  • BiologicalEpcoritamab

    Epcoritamab will be administered subcutaneously in cycles of 21 days and 28 days.

    Also known as: EPKINLY™, GEN3013, DuoBody®-CD3xCD20

  • Drugrituximab, cyclophosphamide, doxorubicin, vincristine and prednisone

    Drug pages: Rituximab · Cyclophosphamide · Doxorubicin · Vincristine · Prednisone

    R-CHOP will be administered intravenously (prednisone may be administered orally) in cycles of 21 days.

  • Venetoclax tablets will be administered orally once daily during the 5-week ramp up period in cycles of 28 or 35 days each.

  • BiologicalEpcoritamab

    Epcoritamab will be administered subcutaneously in cycles of 28 days.

    Also known as: EPKINLY™, GEN3013, DuoBody®-CD3xCD20

  • Lenalidomide capsules will be administered once daily for 21 days in each cycle of 28 days.

  • BiologicalEpcoritamab

    Epcoritamab will be administered subcutaneously in cycles of 28 days.

    Also known as: EPKINLY™, GEN3013, DuoBody®-CD3xCD20

  • Pirtobrutinib tablets will be administered in cycles of 28 days.

  • BiologicalEpcoritamab

    Epcoritamab will be administered subcutaneously in cycles of 28 days.

    Also known as: EPKINLY™, GEN3013, DuoBody®-CD3xCD20

06

What researchers measure

Primary outcomes

  1. Dose Escalation Phase and Safety Run-in (R/R CLL arm): Number of Participants with Dose Limiting Toxicities (DLTs)

    DLT events were defined as clinically significant adverse events (AEs) or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications as assessed per Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 5.0.

    Time frame: During the first cycle for low dose cohorts (Cycle length = 28 days) and for high dose cohorts (Cycle length = 35 days)

  2. Dose Escalation Phase and Safety Run-in: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Up to 5 years

  3. Dose Escalation Phase: Number of Participants with Cytokine Release Syndrome (CRS), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and Clinical Tumor Lysis Syndrome (CTLS)

    CRS and ICANS will be graded based on American Society for Transplantation and Cellular Therapy (ASTCT) criteria. CTLS will be graded according to Cairo-Bishop criteria.

    Time frame: Up to 5 years

  4. Expansion Phase: Overall Response Rate (ORR)

    R/R CLL participants will be assessed according to International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria and the RS participants according to Lugano criteria. ORR based on the Lugano criteria is defined as the percentage of participants who achieve a response of PR or complete remission (CR), prior to initiation of subsequent therapy. The ORR based on the iwCLL criteria is defined as the percentage of participants who achieve a response of PR, CR with incomplete bone marrow recovery (CRi), or CR, prior to the initiation of subsequent therapy.

    Time frame: Up to 5 years

Secondary outcomes

  1. Expansion Phase: Number of Participants with TEAEs and SAEs

    Time frame: Up to 5 years

  2. Dose Escalation Phase and Safety Run-in: ORR (for R/R CLL Participants)

    The ORR is defined as the percentage of participants who achieve a response of PR, CRi, or CR, prior to the initiation of subsequent therapy as assessed by iwCLL criteria.

    Time frame: Up to 5 years

  3. Both Phases and Safety Run-in: Duration of Response (DOR)

    DOR is defined among responders, as the time from the initial documentation of response to the date of disease progression or death, whichever occurs earlier.

    Time frame: Up to 5 years

  4. Both Phases and Safety Run-in: Number of Participants with CR/CRi

    CR and CRi for R/R CLL participants will be assessed according to iwCLL criteria and CR for the RS participants, according to Lugano criteria.

    Time frame: Up to 5 years

  5. Both Phases and Safety Run-in: Time to Response (TTR)

    TTR is defined among responders, as the time between first dose of any study drug and the initial documentation of response.

    Time frame: Up to 5 years

  6. Both Phases and Safety Run-in: Progression Free Survival (PFS)

    PFS is defined as the time from the first dosing date of any study drug and the date of disease progression or death, whichever occurs earlier.

    Time frame: Up to 5 years

  7. Both Phases and Safety Run-in: Overall Survival (OS)

    OS is defined as the time from the first dosing date of any study drug and the date of death due to any cause.

    Time frame: Up to 5 years

  8. Both Phase and Safety Run-in: Time to Next Systemic Anti-cancer Therapy (TTNT)

    TTNT is defined as the time from the first dosing date of any study drug to the first documented administration of subsequent systemic anticancer therapy.

    Time frame: Up to 5 years

  9. Both Phases and Safety Run-in: Area Under the Concentration-time Curve (AUC) in Epcoritamab

    Time frame: Predose and post dose at multiple timepoints at end of each cycle for low dose and high dose cohorts (Cycle length = 28 days, except Cycle 1 for high dose cohorts = 35 Days), up to 5 years

  10. Both Phases and Safety Run-in: Maximum (Peak) Plasma Concentration (Cmax) in Epcoritamab

    Time frame: Predose and post dose at multiple timepoints at end of each cycle for low dose and high dose cohorts (Cycle length = 28 days, except Cycle 1 for high dose cohorts = 35 Days), up to 5 years

  11. Both Phases: Pre-dose (Trough) Concentrations (Cthrough) in Epcoritamab

    Time frame: Predose and post dose at multiple timepoints at end of each cycle for low dose and high dose cohorts (Cycle length = 28 days, except Cycle 1 for high dose cohorts = 35 Days), up to 5 years

  12. Both Phases and Safety Run-in: Time to Reach Cmax (Tmax) in Epcoritamab

    Time frame: Predose and post dose at multiple timepoints at end of each cycle for low dose and high dose cohorts (Cycle length = 28 days, except Cycle 1 for high dose cohorts = 35 Days), up to 5 years

  13. Both Phases and Safety Run-in: Elimination Half-life (T1/2) in Epcoritamab

    Time frame: Predose and post dose at multiple timepoints at end of each cycle for low dose and high dose cohorts (Cycle length = 28 days, except Cycle 1 for high dose cohorts = 35 Days), up to 5 years

  14. Both Phases and Safety Run-in: Total Body Clearance of Drug From Plasma (CL) in Epcoritamab

    Time frame: Predose and post dose at multiple timepoints at end of each cycle for low dose and high dose cohorts (Cycle length = 28 days, except Cycle 1 for high dose cohorts = 35 Days), up to 5 years

  15. Both Phases: Lymphoid Cells for Immunophenotyping

    Evaluation of B cells, T cells and their activation

    Time frame: Up to 5 years

  16. Expansion Phase: Number of Participants with CRS, ICANS and CTLS

    CRS and ICANS will be graded based on ASTCT criteria. CTLS will be graded according to Cairo-Bishop criteria.

    Time frame: Up to 5 years

  17. Expansion Phase and Safety Run-in : Percentage of Participants with Minimal Residual Disease (MRD) Negativity

    MRD negativity rate, is defined as the proportion of participants with at least 1 undetectable MRD result according to the specific threshold, prior to initiation of subsequent therapy.

    Time frame: Up to 5 years

  18. Both Phases and Safety Run-in: Number of Participants with Anti-drug Antibodies (ADA) to Epcoritamab

    Time frame: Up to 5 years

  19. Expansion Phase: Number of Participants with PR

    Time frame: Up to 5 years

  20. Both Phases and Safety Run-in: Duration of MRD Negativity

    The time from first achieving MRD negativity after start of treatment to the MRD conversion to positive.

    Time frame: Up to 5 years

07

Study locations

81 sites
08

References and documents

Publications

  • Kater AP, Janssens A, Eradat H, Offner F, Sandoval-Sus JD, Shadman M, Poulsen CB, Christensen JH, Thompson MC, Guan M, Steele AJ, Rios M, Holst Morch M, Oki T, Valentin R, Bellido M, Eichhorst B. Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial. Lancet Haematol. 2026 Jan;13(1):e8-e21. doi: 10.1016/S2352-3026(25)00327-8. Epub 2025 Dec 8. PubMed 41380698 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Dec 2027, 85 months after the start.

Of 50 industry-sponsored phase 1/2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 104. This study's planned 85 months is close to that.

Counting every sponsor, half of 90 studies reached it within 78 months; a quarter within 51 and three quarters within 103.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2020
First posted
Nov 10, 2020
StartActual
Nov 25, 2020
Primary completionEst.
Dec 2027
CompletionEst.
Feb 2028
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
17 sites added, 17 sites removed
Show 17 added (4 France, 4 Spain, 3 Italy, 3 Poland, 2 Czechia, 1 Netherlands)
  • Fakultni nemocnice Brno · Brno, Czechia
  • Fakultni nemocnice Olomouc · Olomouc, Czechia
  • CHU Hôpital de Brabois Nancy · Vandœuvre-lès-Nancy, France
  • Hôpital Saint-Louis · Paris, France
  • Hôpital Universitaire Pitié-Salpêtrière · Paris, France
  • CHU Clermont Ferrand · Clermont-Ferrand, France
  • AOU Policlinico Sant'Orsola Malpighi IRCCS · Bologna, Italy
  • AOU Policlinico Umberto I · Roma, Italy
  • AOU Città della Salute e della Scienza di Torino · Torino, Italy
  • Universitair Medisch Centrum Utrecht · Utrecht, Netherlands
  • Pratia Medical Center Katowice (Centrum Medyczne Pratia Katowice) · Katowice, Poland
  • Pratia Malopolskie Medical Center Krakow (Pratia Małopolskie Centrum Medyczne Krakow) · Krakow, Poland
  • Aidport sp z o.o. · Skorzewo, Poland
  • Hospital Clinic de Barcelona · Barcelona, Spain
  • Hospital de la Santa Creu i Sant Pau · Barcelona, Spain
  • Hospital Universitario Fundacion Jiménez Díaz · Madrid, Spain
  • Hospital Universitario Virgen Macarena · Seville, Spain
Show 17 removed
  • Fakultni nemocnice Brno · Brno, Czechia
  • Fakultni nemocnice Olomouc · Olomouc, Czechia
  • CHU Hôpital de Brabois Nancy · Vandœuvre-lès-Nancy, France
  • CHU Clermont Ferrand · Clermont-Ferrand, France
  • Hôpital Saint-Louis · Paris, France
  • Hôpital Universitaire Pitié-Salpêtrière · Paris, France
  • AOU Policlinico Sant'Orsola Malpighi IRCCS · Bologna, Italy
  • AOU Policlinico Umberto I · Roma, Italy
  • AOU Città della Salute e della Scienza di Torino · Torino, Italy
  • Universitair Medisch Centrum Utrecht · Utrecht, Netherlands
  • Pratia Medical Center Katowice (Centrum Medyczne Pratia Katowice) · Katowice, Poland
  • Pratia Malopolskie Medical Center Krakow (Pratia Małopolskie Centrum Medyczne Krakow) · Krakow, Poland
  • Aidport sp z o.o. · Skorzewo, Poland
  • Hospital Clinic de Barcelona · Barcelona, Spain
  • Hospital de la Santa Creu i Sant Pau · Barcelona, Spain
  • Hospital Universitario Fundacion Jiménez Díaz · Madrid, Spain
  • Hospital Universitario Virgen Macarena · Seville, Spain
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    17 sites added, 17 sites removed
    Show 17 added (4 France, 4 Spain, 3 Italy, 3 Poland, 2 Czechia, 1 Netherlands)
    • Fakultni nemocnice Brno · Brno, Czechia
    • Fakultni nemocnice Olomouc · Olomouc, Czechia
    • CHU Hôpital de Brabois Nancy · Vandœuvre-lès-Nancy, France
    • Hôpital Saint-Louis · Paris, France
    • Hôpital Universitaire Pitié-Salpêtrière · Paris, France
    • CHU Clermont Ferrand · Clermont-Ferrand, France
    • AOU Policlinico Sant'Orsola Malpighi IRCCS · Bologna, Italy
    • AOU Policlinico Umberto I · Roma, Italy
    • AOU Città della Salute e della Scienza di Torino · Torino, Italy
    • Universitair Medisch Centrum Utrecht · Utrecht, Netherlands
    • Pratia Medical Center Katowice (Centrum Medyczne Pratia Katowice) · Katowice, Poland
    • Pratia Malopolskie Medical Center Krakow (Pratia Małopolskie Centrum Medyczne Krakow) · Krakow, Poland
    • Aidport sp z o.o. · Skorzewo, Poland
    • Hospital Clinic de Barcelona · Barcelona, Spain
    • Hospital de la Santa Creu i Sant Pau · Barcelona, Spain
    • Hospital Universitario Fundacion Jiménez Díaz · Madrid, Spain
    • Hospital Universitario Virgen Macarena · Seville, Spain
    Show 17 removed
    • Fakultni nemocnice Brno · Brno, Czechia
    • Fakultni nemocnice Olomouc · Olomouc, Czechia
    • CHU Hôpital de Brabois Nancy · Vandœuvre-lès-Nancy, France
    • CHU Clermont Ferrand · Clermont-Ferrand, France
    • Hôpital Saint-Louis · Paris, France
    • Hôpital Universitaire Pitié-Salpêtrière · Paris, France
    • AOU Policlinico Sant'Orsola Malpighi IRCCS · Bologna, Italy
    • AOU Policlinico Umberto I · Roma, Italy
    • AOU Città della Salute e della Scienza di Torino · Torino, Italy
    • Universitair Medisch Centrum Utrecht · Utrecht, Netherlands
    • Pratia Medical Center Katowice (Centrum Medyczne Pratia Katowice) · Katowice, Poland
    • Pratia Malopolskie Medical Center Krakow (Pratia Małopolskie Centrum Medyczne Krakow) · Krakow, Poland
    • Aidport sp z o.o. · Skorzewo, Poland
    • Hospital Clinic de Barcelona · Barcelona, Spain
    • Hospital de la Santa Creu i Sant Pau · Barcelona, Spain
    • Hospital Universitario Fundacion Jiménez Díaz · Madrid, Spain
    • Hospital Universitario Virgen Macarena · Seville, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04623541
Lead sponsor
Genmab
Responsible party
Sponsor
First posted
Nov 10, 2020
Start date
Nov 25, 2020
Primary completion
Dec 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Nov 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epcoritamab

Start the discussion